Log In
Print
BCIQ
Print
Print this Print this
 

lucinactant (Surfaxin)

  Manage Alerts
Collapse Summary General Information
Company Discovery Laboratories Inc.
DescriptionHumanized lung surfactant
Molecular Target Not applicable
Mechanism of ActionNA
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationRespiratory distress syndrome (RDS)
Indication DetailsPrevent respiratory distress syndrome (RDS); Prevent respiratory distress syndrome (RDS) in premature infants; Treat acute respiratory distress syndrome (ARDS) in adults; Treat acute respiratory failure (ARF); Treat and prevent respiratory distress syndrome (RDS); Treat or prevent idiopathic respiratory distress syndrome (IRDS) in premature infants; Treat respiratory distress syndrome (RDS) in infants
Regulatory Designation

U.S. - Fast Track (Treat acute respiratory distress syndrome (ARDS) in adults);
U.S. - Orphan Drug (Treat acute respiratory distress syndrome (ARDS) in adults)

Partner

Esteve S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today